Logo-jcvtr

J Cardiovasc Thorac Res. 2024;16(4): 211-221. doi: 10.34172/jcvtr.33230
PMID: 40027370        PMCID: PMC11866776

Review Article

Post-transplant cyclophosphamide-induced cardiotoxicity: A comprehensive review

Azin Alizadehasl 1 ORCID, Bita Shahrami 2,3, Reza Rahbarghazi 4,5, Azam Yalameh Aliabadi 1, Seyedeh Fatemeh Hosseini Jebelli 1, Yasamin Afsari Zonooz 1, Hoda Hakimian 1, Farzaneh Fathi 6, Sara Forati 1 * ORCID, Aysa Rezabakhsh 7 * ORCID

Cited by CrossRef:

1- Woods E, Munjal S, Abidi M, Pantin J, Graves V, Nowak H, Weinstein N, Blankenberger K, Musall K, Prasad P, Goebel W, Johnstone B. Cryopreserved organ donor bone marrow achieves robust engraftment and chimerism in mismatched allogeneic transplantation. Cytotherapy. 2025;:102006 [Crossref]
2- Wang X, Zhu S, Zhao Y, Di X, Cao L, Reiter R, He E, Zhou Y, Kim B, Cheng Y, Ren J. Pervasive environmental contaminant acrolein compromises myocardial geometry and function through the induction of cuproptosis. ABBS. 2025; [Crossref]
3- Chen T, Lin C, Wang S, Chen C, Lin M, Hsieh C, Lin C, Yeh S, Chiu C. NT-proBNP Levels After First-Dose Post-Transplant Cyclophosphamide Predict Early Cardiac Events and Mortality in Allogeneic Stem Cell Transplantation. Transplantation and Cellular Therapy. 2025; [Crossref]
4- Torrent-Rodríguez A, Cascos E, Garcés V, Pérez-López E, Baile-González M, Rodríguez C, Cascón M, Luque M, Esquirol A, Calvo C, Peña-Muñoz F, Fernando I, Ormtegi I, Marín A, Fernández-Luis S, Domínguez-García J, Fernández S, Lorenzo J, de Sanmamed Girón M, Pinedo L, García-Maño L, González-Rodriguez A, Torrado T, Filaferro S, Basalobre P, Ortí G, Rovira M, Chacón M, Salas M. Safety of Post-Transplant Cyclophosphamide-Based Prophylaxis in AML Patients with Pre-Existing Cardiac Morbidity Undergoing Allogeneic Hematopoietic Cell Transplantation. Cancers. 2025;17(19):3128 [Crossref]
5- Mao H, Zhao X, Mo S, Wang H, Liu R, Xie Y, Huang Y, Zheng Y, Hua Y. Bone-protective effects of deer-hide gelatin in cyclophosphamide-induced osteoporosis rats. Front Pharmacol. 2025;16 [Crossref]
6- Guida F, Fabi M, Balducci A, Zama D, Masetti R, Mercolini F, Belotti T, Cantarini M, Facchini E, Legnani E, Melchionda F, Bartolacelli Y, Ciuca C, Gesuete V, Prete A, Donti A, Lanari M. Risk Stratification for Cardiotoxicity in Childhood Cancer Survivors: State-of-the-Art Review and a Novel Two-Step Approach. Cancers. 2025;17(23):3740 [Crossref]
7- Barriga F. Antithymocyte globulin and posttransplant cyclophosphamide in graft vs. host disease prophylaxis: comparison or combination. 2025;32(6):301 [Crossref]
8- Torrent A, Cascos E, Carcelero E, Riu G, Monge-Escartín I, Ruiz-Boy S, Suárez-Lledó M, Charry P, Cid J, Lozano M, Guardia L, Rosiñol L, Fernández-Avilés F, Martínez C, Carreras E, Rovira M, Salas M. Validation of the CARE-BMT Score and Proposal of a Modified Risk Model with Post-Transplant Cyclofosfamide for Predicting Early Cardiac Events after Allo-HCT. Transplantation and Cellular Therapy. 2025; [Crossref]